New Delhi: Diagnostic services provider Dr Lal PathLabs Ltd on Thursday said its board of directors has approved a 70 per cent stake acquisition in Gujarat-based SN Genelab for about Rs 168 crore.
The transaction also includes a performance-linked earn-out capped at Rs 31.5 crore, the company said in a regulatory filing.
Following the acquisition, SN Genelab will become a subsidiary of Dr Lal PathLabs.
Dr Lal PathLabs aims to strengthen the company’s expertise in genomics and broaden its portfolio of advanced diagnostic services.
The transaction is expected to be completed by November 30, 2026, as per the filing.
Incorporated on December 16, 2013, in Gujarat, SN Genelab provides diagnostic genomics services.
The company posted a turnover of Rs 57.96 crore in FY26 compared to Rs 53.36 crore in FY25 and Rs 43.27 crore in FY24, the filing added.
The company stated that the proposed transaction does not fall within the ambit of related-party transactions and requires no governmental or regulatory approvals.
